

DISMANTLING STRUCTURAL RACISM IN PSYCHIATRY: CHALLENGES AND OPPORTUNITIES

Ruth S. Shim, MD, MPH

Luke & Grace Kim Professor in Cultural Psychiatry

Professor of Clinical Psychiatry

University of California, Davis

DISCLOSURE/DISCLAIMER

- **THIS IS A DIFFICULT AND UNCOMFORTABLE TOPIC**
- **COMPLEX FEELINGS OFTEN EMERGE, INCLUDING GUILT, ANGER, RESENTMENT, AND DEFENSIVENESS**
- **YOU MAY PERCEIVE ME OF ACCUSING YOU OF BEING RACIST/SEXIST/ETC.**
- **YOU MAY FEEL I HAVE A SPECIFIC POLITICAL AGENDA OR THAT I LACK OBJECTIVITY**

**“I’M NOT INTERESTED
IN ANYBODY’S GUILT.**

**GUILT IS A LUXURY THAT WE
CAN NO LONGER AFFORD.**

**I KNOW YOU DIDN’T DO IT, AND I DIDN’T
DO IT EITHER, BUT I AM RESPONSIBLE
FOR IT BECAUSE I AM A MAN AND
A CITIZEN OF THIS COUNTRY AND
YOU ARE RESPONSIBLE FOR IT,
FOR THE VERY SAME REASON.”**



TALKING ABOUT STRUCTURAL RACISM IN PSYCHIATRY

- **WE HAVE BEEN SOCIALIZED TO BELIEVE THAT IT IS NOT POLITE TO TALK ABOUT RACE**

This begins early, as children in the US (and elsewhere)

- **PHYSICIANS HAVE NOT BEEN TAUGHT ABOUT THE CONNECTION BETWEEN RACISM AND HEALTH**

Medical school has a long tradition of teaching biological determinism

- **ARE THE TIMES A-CHANGIN'?**

Some feel that there is an overemphasis and over-correction happening now

THE PROBLEM WITH RACE-BASED CLINICAL CARE

- RACE IS A **SOCIAL AND POLITICAL CONSTRUCT**
- RACE IS A **ROUGH AND IMPRECISE PROXY** FOR CULTURE, GENETICS, AND SOCIOECONOMIC STATUS
- RACE CANNOT BE ACCURATELY BIOLOGICALLY CATEGORIZED
- YET, WE USE RACE TO CONFIRM ASSUMPTIONS/PREJUDICES/BIASES ABOUT OUR PATIENTS

HOW DID WE GET HERE?

THE
AN AMERICAN
DREAM



HISTORICAL ORIGINS OF PSYCHIATRIC PSEUDOSCIENCE

DRAPETOMANIA

“If any one or more of them, at any time, are inclined to raise their heads to a level with their master or overseer, humanity and their own good requires that they should be punished until they fall into that submissive state which was intended for them to occupy. They have only to be kept in that state, and treated like children to prevent and cure them from running away.”

DYSAESTHESIA AETHIOPICA

After the prescribed “course of treatment” the slave will “look grateful and thankful to the white man whose compulsory power...has restored his sensation and dispelled the mist that clouded his intellect.”

HEALTH DISPARITIES:

**DIFFERENCES IN HEALTH STATUS AMONG DISTINCT
SEGMENTS OF THE POPULATION INCLUDING
DIFFERENCES THAT OCCUR BY GENDER, RACE OR
ETHNICITY, EDUCATION OR INCOME, DISABILITY,
OR LIVING IN VARIOUS GEOGRAPHIC LOCALITIES**

HEALTH INEQUITIES:
DISPARITIES IN HEALTH THAT ARE A RESULT OF
SYSTEMIC, AVOIDABLE, AND UNJUST SOCIAL
AND ECONOMIC POLICIES AND PRACTICES
THAT CREATE BARRIERS TO OPPORTUNITY



KEY CONCEPTS

TYPES OF DISCRIMINATION



LEGAL



ILLEGAL



OVERT



COVERT



INTERPERSONAL

(Individual)



INSTITUTIONAL

(Organizational)



STRUCTURAL

(Systemic)

PRINCIPLES OF SOCIAL INJUSTICE

- **ESSENTIALISM**

The belief that there are distinct, unchanging, and natural characteristics that define social groups and facilitate their categorization

- **ERASURE OF CONTEXT**

Failure to consider sociohistorical context when seeking to understand the etiology of inequities

- **BIOLOGICAL DETERMINISM**

The false belief that racial groups are biologically and genetically different

- **CULTURAL DETERMINISM**

The false belief that differences in racial groups are the result of cultural factors (e.g., ethnocentrism)

TYPES OF OPPRESSION

EXPLOITATION

The unequal exchange of one group's labor and energies for another group's advantage and advancement

CULTURAL IMPERIALISM

Establishing the ruling class culture as the norm; othering of groups that are not part of the dominant culture

POWERLESSNESS

Oppressed groups lack power and are blocked from routes to gaining power

MARGINALIZATION

Expelling specific groups from meaningful participation in society

VIOLENCE


Threats and experiences of physical and structural violence

STRUCTURAL RACISM

A SYSTEM IN WHICH **PUBLIC POLICIES, INSTITUTIONAL PRACTICES, CULTURAL REPRESENTATIONS, AND OTHER NORMS** WORK IN VARIOUS, OFTEN REINFORCING WAYS TO **PERPETUATE RACIAL GROUP INEQUITY.**



**THIS SYSTEM IDENTIFIES
DIMENSIONS OF OUR HISTORY AND
CULTURE THAT HAVE ALLOWED
PRIVILEGES ASSOCIATED WITH
“WHITENESS” AND DISADVANTAGES
ASSOCIATED WITH “COLOR” TO
ENDURE AND ADAPT OVER TIME**



**STRUCTURAL RACISM IS NOT SOMETHING THAT
A FEW PEOPLE OR INSTITUTIONS CHOOSE
TO PRACTICE. INSTEAD, IT HAS BEEN A
FEATURE OF THE SOCIAL, ECONOMIC, AND
POLITICAL SYSTEMS IN WHICH WE ALL EXIST**

**STRUCTURAL MECHANISMS DO NOT REQUIRE
THE ACTIONS OR INTENTIONS OF OTHERS**

**EVEN IF INTERPERSONAL DISCRIMINATION
WAS ELIMINATED TODAY,**

**RACIAL AND ETHNIC INEQUITIES WOULD REMAIN
DUE TO PERSISTENCE OF STRUCTURAL RACISM**

STRUCTURAL RACISM IN PSYCHIATRY

HOW STRUCTURAL RACISM IMPACTS HEALTH



“THE WAR ON DRUGS”



RESIDENTIAL SEGREGATION



IMMIGRATION POLICY



SOCIAL SECURITY ACT OF 1935



MENTAL HEALTHCARE

PRIOR TO THE EARLY 1960S, PSYCHIATRISTS ASSESSMENTS OF SYMPTOMS OF MENTAL ILLNESS AT IONIA STATE HOSPITAL INCLUDED:

“WASN'T ABLE TO TAKE CARE OF HER FAMILY AS SHE SHOULD”

“CAN'T DO HER HOUSEWORK”

“TALKED TOO LOUDLY AND EMBARRASSED HER HUSBAND”

“PERHAPS [SHE] REBELLED AGAINST A PATRIARCHAL SYSTEM, AND A PATRIARCHAL DIAGNOSIS, THAT ALLOWED WHITE MALE DOCTORS AND HER WHITE MALE HUSBAND TO BE THE ARBITERS OF HER MENTAL HEALTH.... HOWEVER, THE MOST IMPORTANT ASPECT... IS THAT [HER] DEFIANCE WAS INTERPRETED AS A SYMPTOM BUT NOT AS A THREAT.”



**You can't set her free.
But you can help her
feel less anxious.**

You know this woman.

She's anxious, tense, irritable. She's felt this way for months. Beset by the seemingly insurmountable problems of raising a young family, and confined to the home most of the time, her symptoms reflect a sense of inadequacy and isolation. Your reassurance and guidance may have helped some, but not enough. SERAX (oxazepam) cannot change her environment, of course. But it can help relieve anxiety, tension, agitation and irritability, thus strengthening her ability to cope with day-to-day problems. Eventually—as she regains confidence and composure—your counsel may be all the support she needs.

Indicated in anxiety, tension, agitation, irritability, and anxiety associated with depression.

May be used in a broad range of patients, generally with considerable dosage flexibility.

Contraindications: History of previous hypersensitivity to oxazepam. Oxazepam is not indicated in psychoses.

Precautions: Hypotensive reactions are rare, but use with caution where complications could ensue from a fall in blood pressure, especially in the elderly. One patient exhibiting drug dependency by taking a chronic overdose developed upon cessation questionable withdrawal symptoms. Carefully supervise dose and amounts prescribed, especially for patients prone to overdose; excessive prolonged use in susceptible patients (alcoholics, ex-addicts, etc.) may result in dependence or habituation. Reduce dosage gradually after prolonged excessive dosage to avoid possible epileptiform seizures. Caution patients against driving or operating machinery until absence of drowsiness or dizziness is ascertained. Warn patients of possible reduction in alcohol tolerance. Safety for use in pregnancy has not been established.

Not indicated in children under 6 years; absolute dosage for 6 to 12 year-olds not established.

Side Effects: Therapy-interrupting side effects are rare. Transient mild drowsiness is common initially; if persistent, reduce dosage. Dizziness, vertigo and headache have also occurred infrequently; syncope, rarely. Mild paradoxical reactions (excitement, stimulation of affect) are reported in psychiatric patients. Minor diffuse rashes (morbilliform, urticarial and maculopapular) are rare. Nausea, lethargy, edema, slurred speech, tremor and altered libido are rare and generally controllable by dosage reduction. Although rare, leukopenia and hepatic dysfunction including jaundice have been reported during therapy. Periodic blood counts and liver function tests are advised. Ataxia, reported rarely, does not appear related to dose or age.

These side reactions, noted with related compounds, are not yet reported: paradoxical excitation with severe rage reactions; hallucinations; menstrual irregularities; change in ECG pattern; blood dyscrasias (including agranulocytosis); blurred vision; diplopia; incontinence; stupor; disorientation; fever, euphoria and dysmetria.

Availability: Capsules of 10, 15 and 30 mg. oxazepam.

To help you relieve anxiety and tension

Serax[®]
(oxazepam)



“AT THE TIME, COMMON CONCEPTUALIZATIONS OF SCHIZOPHRENIA DID NOT INCLUDE SYMPTOMS OF PARANOIA, AGGRESSION, OR HOSTILITY. INSTEAD, SCHIZOPHRENIA WAS CONCEPTUALIZED AS A DISEASE RESULTING FROM EARLY-LIFE PSYCHOLOGICAL TRAUMA, OFTEN COMMITTED AT THE HANDS OF A SCHIZOPHRENOGENIC MOTHER.”

The “Protest” Psychosis

A Special Type of Reactive Psychosis

Walter Bromberg, MD, and Franck Simon, PhD, Brooklyn, NY

THE PURPOSE of this paper is to identify a specific type of reactive psychosis related in part to recent social-political events. It is well known that of the external stresses that trigger many psychotic reactions, the content of the clinical picture may be colored by or formed of political events of national or international import. Thus, delusional schizophrenics complained of Bolshevik persecution in the 1920's and interference by space figures in the 1960's. In the reactive psychosis particularly, a close relation exists between external stresses and the explicated clinical syndrome.

criminal trial, or following conviction and sentencing in a criminal trial. The particular symptomatology we have observed, for which the term “protest psychosis” is suggested, is influenced by social pressures (the Civil Rights Movement), dips into religious doctrine (the Black Muslim Group), is guided in content by African subcultural ideologies and is colored by a denial of Caucasian values and hostility thereto. This protest psychosis among prisoners is virtually a repudiation of “white civilization.”

The cases to be presented characteristically arise among American Negroes who

TERM COINED TO DESCRIBE A REACTIVE PSYCHOSIS ARISING IN BLACK MALES AS A RESULT OF “THE STRESS OF ASSERTING CIVIL RIGHTS IN THE US.”

BROMBERG AND SIMON (1968) LIKENED SYMPTOMS TO SCHIZOPHRENIA, PARANOID TYPE, BUT ALSO DESCRIBED HALLUCINATIONS OF AFRICAN THEMES, ADOPTION OF ISLAMIC DOCTRINE, AND PROMOTION OF ANTI-WHITE MINDSETS

THE PROTEST PSYCHOSIS, BIOLOGICAL DETERMINISM, AND ERASURE OF CONTEXT

- RESEARCHERS CLAIMED THAT BLACK PSYCHIATRIC PATIENTS HAD **HIGHER MEASURES OF HOSTILITY** THAN WHITE PSYCHIATRIC PATIENTS, STEMMING FROM “DELUSIONAL BELIEFS THAT THEIR CIVIL RIGHTS WERE BEING COMPROMISED OR VIOLATED.”
- LARGE-SCALE **PATHOLOGIZING OF THE TENETS OF THE CIVIL RIGHTS MOVEMENT** BY EQUATING THESE IDEAS WITH PARANOID DELUSIONS ALLOWED CERTAIN SECTORS OF SOCIETY **A MECHANISM FOR REMOVING THREATS TO THE STATUS QUO** IN THE NAME OF SAFETY AND MENTAL HEALTH

Assaultive and belligerent?



Cooperation often begins with **HALDOL** (haloperidol) a first choice for starting therapy

Acts promptly to control aggressive, assaultive behavior

Several studies have revealed the rapid effectiveness of HALDOL (haloperidol) in controlling aggressive and potentially assaultive behavior. In one of the earlier studies, 80% of the patients in a group of violent patients (mean age 35 years) who were treated with HALDOL responded satisfactorily during treatment with HALDOL. Response control can be achieved rapidly, frequently within a few days when the treatment team used the initial control of a newly onset psychotic episode.

Usually leaves patients relatively alert and responsive

Although some reactions of drowsiness have been observed, marked sedation with HALDOL (haloperidol) is rare. In a hospital study with control patients, the patients remained alert and were amenable to psychotherapeutic intervention. Another investigation reports that HALDOL "normalizes behavior and produces a response to the environment that allows more effective use of the social milieu and the therapeutic community."

Reduces risk of serious adverse reactions

HALDOL (haloperidol) is a butyrophenone, a different class of antipsychotic medication from the phenothiazines. Extrapyramidal side effects and other serious adverse reactions have not been reported. There is also low likelihood of adverse reactions such as liver damage, acute changes in heart rate, orthostatic hypotension, and other risks. The most frequent side effects of HALDOL (haloperidol)—orthostatic hypotension, acute changes in heart rate, and other risks—were usually transient and well tolerated.

Information relating to Indications, Contraindications, Warnings, Precautions and Adverse Reactions, please turn page.

ORIGINAL REPORT

Persistence of racial disparities in prescription of first-generation antipsychotics in the USA

Thomas B. Cook^{1*}, Gloria M. Reeves², James Teufel¹ and Teodor T. Postolache^{2,3,4}

¹Department of Public Health, Mercyhurst Institute of Public Health, Mercyhurst University, Erie, PA, USA
²Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA
³Veterans Integrated Service Network (VISN) 5, Mental Illness Research Education and Clinical Center (MIRECC), Baltimore, MD, USA
⁴Rocky Mountain MIRECC, Denver, CO, USA

ABSTRACT

Purpose The aim of this study was to estimate the prevalence of first-generation antipsychotics (FGA) prescribed for treatment of psychiatric and neurological conditions and use of benzotropine to reduce extrapyramidal side effects (EPS) by patient race/ethnicity in a nationally representative sample of adult outpatient visits.

Methods The study sample included all outpatient visits ($N=8154$) among patients aged 18–69 years where a prescription for one or more antipsychotics was recorded across 6 years of the National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey (2005–2010). Use of FGA was compared by race/ethnicity using multiple logistic regression models accounting for patient and clinical characteristics stratified by neighborhood poverty rate. Frequency of EPS was determined by use of benzotropine to reduce or prevent EPS.

Results Black patients were significantly more likely than White patients to use FGA (odds ratio = 1.48, $p=0.040$) accounting for psychiatric and neurological diagnoses, treatment setting, metabolic factors, neighborhood poverty, and payer source. Black patients were more than twice as likely as White patients to receive higher-potency FGA (haloperidol or fluphenazine), particularly in higher-poverty areas (odds ratio = 2.50, $p<0.001$). Use of FGA, higher among Black than White patients, was positively associated with use of benzotropine to reduce EPS.

Conclusions Racial disparities in the pharmacological treatment of severe mental disorders persist 30 years after the introduction of second-generation antipsychotics. The relatively high frequency of FGA of use among Black patients compared with White patients despite more Food and Drug Administration-approved indications and lower EPS risk for second-generation antipsychotics requires additional research. Copyright © 2015 John Wiley & Sons, Ltd.

KEY WORDS—antipsychotics; racial disparities; prescribing patterns; pharmacoepidemiology

Ethnicity and Diagnosis in Patients With Affective Disorders

Stephen M. Strakowski, M.D.;

Paul E. Keck, Jr., M.D.; Lesley M. Arnold, M.D.; Jacqueline Collins, M.D.;
Rodgers M. Wilson, M.D.; David E. Fleck, Ph.D.; Kimberly B. Corey, M.A.;
Jennifer Amicone, M.S.W.; and Victor R. Adebimpe, M.D.

Background: Clinically, African American psychiatric patients are disproportionately diagnosed with schizophrenia compared with white patients. Why this occurs is unknown. Extending prior work, the authors hypothesized that first-rank symptoms distract clinicians so that they fail to identify affective disorders in African Americans.

Method: 195 African American and white patients with at least 1 psychotic symptom (delusions, hallucinations, or prominent thought disorder) at admission were recruited from January 1, 1998, through May 31, 2001. Each patient received 3 independent DSM-IV diagnoses: a clinical diagnosis, a structured-interview diagnosis, and an expert-consensus diagnosis. The expert-consensus diagnoses were derived from the structured interviews, which were audio-

Received July 11, 2002; accepted Nov. 12, 2002. From the Bipolar and Psychotic Disorders Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio (Drs. Strakowski, Keck, Arnold, Collins, Wilson, and Fleck and Mss. Corey and Amicone); and the Department of Psychiatry, Rush Medical College (Dr. Wilson) and Mercy Providence Hospital (Dr. Adebimpe), Pittsburgh, Pa.

Supported by National Institute of Mental Health award MH56352. Dr. Keck is a consultant for Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Ortho-McNeil, Pfizer, and Shire and has received grant/research support from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Ortho-McNeil, Merck, Pfizer, and UCB Pharma. The authors thank Mary Fariello, who organized the data collection for this project, and Kelly Wilder-Willis, Ph.D., for help with some diagnostic assessments.

Corresponding author and reprints: Stephen M. Strakowski, M.D., Director, Bipolar and Psychotic Disorders Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267-0559 (e-mail: strakosm@email.uc.edu).

In 1980s and 1990s, Black men were diagnosed with paranoid schizophrenia at a rate 5-7 times that of White men

A Naturalistic Study of Racial Disparities in Diagnoses at an Outpatient Behavioral Health Clinic

Michael A. Gara, Ph.D., Shula Minsky, Ed.D., Steven M Silverstein, Ph.D., Theresa Miskimen, M.D., Stephen M. Strakowski, M.D.

Objective: The authors examined electronic medical record (EMR) outpatient data to determine whether African Americans with schizophrenia or schizoaffective disorder were more likely than non-Latino whites to screen positive for major depression.

Methods: EMR data for 1,657 patients at Rutgers University Behavioral Health Care certified community outpatient clinics were deidentified and accrued for 9 months starting July 1, 2017. A Fisher's exact test was used to compare differences in the proportion of patients with positive screens for major depression (cutoff score of ≥ 15 on the nine-item Patient Health Questionnaire) among African-American and


($p < .003$) to screen positive for major depression. The between-group difference in positive screens was not significant among patients diagnosed as having schizoaffective disorder.

Conclusions: The results are consistent with findings from a large body of literature suggesting that racial differences in the diagnosis of schizophrenia in the United States result in part from clinicians underemphasizing the relevance of mood symptoms among African Americans compared with other racial-ethnic groups. If the results are replicated, a case could be made that routine screen-

TODAY...BLACK PATIENTS ARE MORE LIKELY THAN WHITE PATIENTS TO BE:

- **HOSPITALIZED INVOLUNTARILY**
- **ADMINISTERED HIGHER DOSES OF ANTIPSYCHOTICS**
- **ADMINISTERED MEDICATIONS AGAINST THEIR WILL**
- **SECLUDED AND RESTRAINED**


IN 2018:



**OF BLACK ADULTS
WITH ANY MENTAL
ILLNESS RECEIVED NO
TREATMENT**



**OF LATINX ADULTS
WITH ANY MENTAL
ILLNESS RECEIVED NO
TREATMENT**



**OF BLACK ADULTS
WITH SERIOUS MENTAL
ILLNESS RECEIVED NO
TREATMENT**



**OF LATINX ADULTS
WITH SERIOUS MENTAL
ILLNESS RECEIVED NO
TREATMENT**



**COST IS THE MOST COMMONLY CITED
REASON FOR NOT SEEKING CARE
TWICE AS OFTEN AS MINIMIZATION OF SYMPTOMS
AND NEARLY FIVE TIMES AS OFTEN AS STIGMA**

WHERE DO WE NEED TO GO?

Inequality

Unequal access to opportunities



Source: @GuncHerseth in the 2019 Design in Tech Report

Equality?

Evenly distributed tools and assistance



Source: @GuncHerseth in the 2019 Design in Tech Report

Equity


Custom tools that identify and address inequality



Source: @GuncHerseth in the 2019 Design in Tech Report

Justice

Fixing the system to offer equal access to both tools and opportunities



Source: @GuncHerseth in the 2019 Design in Tech Report

DISMANTLING STRUCTURAL RACISM AND SOCIAL INJUSTICE IN MENTAL HEALTH

1 EDUCATION AND
SELF-REFLECTION





2 PROMOTE SOCIAL NORMS OF INCLUSION,
EQUITY, AND RESPECT

3 ADVOCATE FOR RACIALLY EQUITABLE PUBLIC POLICIES

4 SPEAK UP AND TAKE A STAND

EDUCATION AND SELF-REFLECTION









SCENE ON RADIO

Seeing White

A 14-part documentary series exploring whiteness in America—where it came from, what it means, and how it works.



PRACTICING CULTURAL HUMILITY



- COMMIT TO A **LIFELONG PROCESS OF SELF-EVALUATION AND SELF-CRITIQUE**
- DESIRE TO **FIX POWER IMBALANCES BETWEEN PROVIDERS AND CLIENTS**
- **DEVELOP COMMUNITY PARTNERSHIPS TO ADVOCATE WITHIN THE LARGER ORGANIZATIONS IN WHICH WE PARTICIPATE**



**PROMOTE SOCIAL
NORMS OF INCLUSION,
EQUITY, AND RESPECT**



“WE CAN DISAGREE AND STILL LOVE EACH OTHER, UNLESS YOUR DISAGREEMENT IS ROOTED IN MY OPPRESSION AND DENIAL OF MY HUMANITY AND RIGHT TO EXIST.”

-James Baldwin

PROMOTING SOCIAL NORMS OF INCLUSION, EQUITY, AND RESPECT

1 ENFORCE SOCIAL NORMS OF INCLUSION AND EQUITY

2 EDUCATE OR LEGISLATE TO CHANGE SOCIAL NORMS

3 OBSERVE AND CHALLENGE YOUR IMPLICIT BIASES

4 EVALUATE AND BREAK DOWN UNNECESSARY HIERARCHIES

ADVOCATE FOR RACIALLY EQUITABLE PUBLIC POLICIES



**“MEDICINE IS A SOCIAL SCIENCE, AND POLITICS IS
NOTHING ELSE BUT MEDICINE ON A LARGE SCALE.”**

-RUDOLPH VIRCHOW

“ALL POLICIES ARE HEALTH POLICIES”

1 TAKE ACTION BEYOND THE WALLS OF CLINICS, HOSPITALS, AND TREATMENT CENTERS

2 ADVOCATE FOR POLICIES THAT ADDRESS SOCIAL DETERMINANTS OF MENTAL HEALTH

3 COMMUNICATE WITH ELECTED OFFICIALS AND PROMOTE EQUITABLE REPRESENTATION

4 FORM CROSS-SECTOR COLLABORATIONS AND COMMUNITY COALITIONS

**“IF YOU SEE SOMETHING THAT IS NOT RIGHT,
NOT FAIR, NOT JUST, YOU HAVE A MORAL
OBLIGATION TO DO SOMETHING ABOUT IT.”**

